Neumora Therapeutics (NMRA) Cash from Financing Activities (2022 - 2026)
Neumora Therapeutics' Cash from Financing Activities came in at $9.29 million for Q2 2026, down 49.7% from $18.46 million a year earlier and down 14.6% from the prior quarter.
Powered by 
Analysis
Neumora Therapeutics (NMRA) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Neumora Therapeutics reported Cash from Financing Activities of $78.8 million, up 121.6% year-over-year; for FY2025, it came in at $77.09 million, up 256.8% from FY2024.
- Cash from Financing Activities carries a three-year compound annual growth rate of -12.7% (FY2022 to FY2025).
- Going back by year, Cash from Financing Activities was $21.6 million in FY2024 (-90.7%), $231.94 million in FY2023 (+100.4%) and $115.74 million in FY2022.
- The five-year range for quarterly Cash from Financing Activities is -$481,000 (Q4 2023) to $232.02 million (Q3 2023).
- Year-over-year, Cash from Financing Activities increased in two of the last four quarters, with growth averaging 181.0%.
- Business Quant data shows NMRA's Cash from Financing Activities at $10.88 million (Q1 2026), $58.77 million (Q4 2025) and -$136,000 (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 8.43 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | -8.78 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | -5.05 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 1.76 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | -2.02 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | -3.89 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | -1.48 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 2.34 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | -3.66 Bn |
| 10 | Neumora Therapeutics | 78.88 Mn | -539.08 Mn | - | 9.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.29 Mn |
| Mar 31, 2026 | 10.88 Mn |
| Dec 31, 2025 | 58.77 Mn |
| Sep 30, 2025 | -136,000.00 |
| Jun 30, 2025 | 18.46 Mn |
| Dec 31, 2024 | 15.57 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 2.65 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Dec 31, 2023 | -481,000.00 |
| Sep 30, 2023 | 232.02 Mn |
| Jun 30, 2023 | 292,000.00 |
| Mar 31, 2023 | 101,000.00 |
| Dec 31, 2022 | 26.83 Mn |
API Access
Neumora Therapeutics Cash from Financing Activities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=NMRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-from-financing-activities", "ticker": "NMRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-from-financing-activities&ticker=NMRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();